# Chemomab Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chemomab-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Tel Aviv, Israel
- Website: www.chemomab.com
- Total disclosed funding: $15M
- Latest round: Series B (Dec 4, 2017)
- Investors on record: 3

## About

Established in 2011 and based in Tel Aviv, Israel, Chemomab Therapeutics Ltd. operates as a biopharmaceutical company that develops monoclonal antibodies for the treatment of immune-mediated and fibrotic disorders. In July 2024, Chemomab Therapeutics Ltd. raised USD 10 million in PIPE funding from returning investors OrbiMed Advisors, and Sphera Funds Management, with participation from new investor HBM Partners.

The CM-101 is the firm’s lead clinical candidate, is a monoclonal antibody that targets CCL24. The novel CM-101 proprietary platform hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. The product interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. The organization is advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).

Chemomab plans to use the March 2021 funding to advance the Chemomab pipeline.

## Funding rounds

- Series B, Dec 4, 2017, $10M — OrbiMed Advisors, Activate Venture Partners, SBI JI Innovation Advisory
- Series A, Sep 3, 2016, $5M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Activate Venture Partners (https://capitalatlas.ai/funds/activate-venture-partners) — Series B
- SBI JI Innovation Advisory (https://capitalatlas.ai/funds/sbi-ji-innovation-advisory) — Series B